Compare Stocks: ARDX, OGN, GPCR, and TARS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.72 -2.1%	$4.69	$3.68 ▼ $8.40	$926.99M	0.7	4.26 million shs	2.53 million shs
GPCR Structure Therapeutics	$46.81 -2.1%	$50.83	$18.49 ▼ $94.90	$3.26B	-1.45	874,290 shs	186,949 shs
OGN Organon & Co.	$13.78 +0.1%	$13.60	$5.69 ▼ $13.78	$3.62B	1.52	5.65 million shs	2.59 million shs
TARS Tarsus Pharmaceuticals	$83.11 +0.4%	$65.08	$48.20 ▼ $85.25	$3.65B	0.54	743,307 shs	504,252 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+1.06%	-0.78%	-23.69%	-29.63%	-40.63%
GPCR Structure Therapeutics	+1.42%	-3.14%	-1.16%	+22.38%	+138.05%
OGN Organon & Co.	+0.04%	+0.04%	+1.55%	+2.84%	+46.46%
TARS Tarsus Pharmaceuticals	+11.76%	+17.14%	+34.96%	+37.16%	+41.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.72 -2.1%	$4.69	$3.68 ▼ $8.40	$926.99M	0.7	4.26 million shs	2.53 million shs
GPCR Structure Therapeutics	$46.81 -2.1%	$50.83	$18.49 ▼ $94.90	$3.26B	-1.45	874,290 shs	186,949 shs
OGN Organon & Co.	$13.78 +0.1%	$13.60	$5.69 ▼ $13.78	$3.62B	1.52	5.65 million shs	2.59 million shs
TARS Tarsus Pharmaceuticals	$83.11 +0.4%	$65.08	$48.20 ▼ $85.25	$3.65B	0.54	743,307 shs	504,252 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+1.06%	-0.78%	-23.69%	-29.63%	-40.63%
GPCR Structure Therapeutics	+1.42%	-3.14%	-1.16%	+22.38%	+138.05%
OGN Organon & Co.	+0.04%	+0.04%	+1.55%	+2.84%	+46.46%
TARS Tarsus Pharmaceuticals	+11.76%	+17.14%	+34.96%	+37.16%	+41.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.75	Moderate Buy	$13.90	273.66% Upside
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.91	136.93% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.27% Downside
TARS Tarsus Pharmaceuticals	2.78	Moderate Buy	$90.50	8.89% Upside

Current Analyst Ratings Breakdown

Latest ARDX, OGN, GPCR, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/7/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $14.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00
8/7/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$113.00 ➝ $110.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	2.28	N/A	N/A	$0.60 per share	6.20
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$19.45 per share	N/A
OGN Organon & Co.	$6.22B	0.58	$5.79 per share	2.38	$3.83 per share	3.60
TARS Tarsus Pharmaceuticals	$451.36M	8.08	N/A	N/A	$7.90 per share	10.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	15.50	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.90	4.01	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	145.81	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest ARDX, OGN, GPCR, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest ARDX, OGN, GPCR, and TARS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
GPCR Structure Therapeutics	N/A	20.75	20.75
OGN Organon & Co.	8.43	1.95	1.44
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
GPCR Structure Therapeutics	91.78%
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
GPCR Structure Therapeutics	5.50%
OGN Organon & Co.	1.62%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	249.19 million	235.98 million	Optionable
GPCR Structure Therapeutics	136	69.62 million	65.79 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

ARDX, OGN, GPCR, and TARS Headlines

Recent News About These Companies

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

4 hours ago | globenewswire.com

The Manufacturers Life Insurance Company Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

September 3 at 4:32 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 6.5% Higher - Should You Buy?

September 2 at 12:39 PM | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

September 1 at 4:30 PM | globenewswire.com

Hsbc Holdings PLC Makes New $2.43 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

August 31 at 5:11 AM | marketbeat.com

Canada Pension Plan Investment Board Acquires Shares of 98,900 Tarsus Pharmaceuticals, Inc. $TARS

August 31 at 3:51 AM | marketbeat.com

Freestone Grove Partners LP Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Acquires New Position in Tarsus Pharmaceuticals, Inc. $TARS

August 28, 2026 | marketbeat.com

90,969 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Connor Clark & Lunn Investment Management Ltd.

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $7.91 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS